Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer

Heger, Zbyněk; Polanská, Hana; Křížková, Soňa; Raudenská, Martina; Dostálová, Simona; Moulick, Amitava; Masařík, Michal; Adam, Vojtěch

doi:10.1016/j.colsurfb.2016.11.023

Cited by 19 publications

(12 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a number of antitumor drugs have been approved and used for lung cancer therapy, the cancer-associated mortality rate remains high. This may primarily be attributed to late diagnosis and low response to chemotherapy (1,2). Therefore, at present, the 5-year survival rate of patients with lung cancer worldwide is ~15% (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Bergapten induces G1 arrest of non‑small cell lung cancer cells, associated with the p53‑mediated cascade

Chiang

Lin

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

The pr incipal subtype of lung cancer, non-small cell lung cancer (NSCLC) is a life-threatening malignancy that causes high mortality rates. Bergapten (5-methoxypsoralen) has been identified to possess anticancer activity against a number of carcinomas. In the present study, the effects of bergapten on NSCLC cells were investigated. The cell viability was determined by MTT assay. Cell cycle distribution was analyzed using flow cytometry. Protein expression and kinase cascade were demonstrated using western blot analysis. The results demonstrated that treatment with bergapten (50 µM for 48 h) inhibited the viability of A549 and NCI-H460 NSCLC cells to 79.1±2.8% and 74.5±3.1%, respectively, compared with the controls. It was identified that bergapten induced G1 phase accumulation in A549 and NCI-H460 cells between ~58 and 75% (P<0.01). In addition, bergapten significantly increased the sub-G1 phase ratio to ~9% (P<0.05) in the two cell types. Further investigation demonstrated that bergapten upregulated the expression of cellular tumor antigen p53 (p53) and its downstream proteins cyclin-dependent kinase inhibitor 1 and cyclin-dependent kinase inhibitor 1B, whereas, it downregulated the expression of cyclin D1 and CDK4. Overall, these results suggested that bergapten may inhibit cell viability and trigger G1 arrest and apoptosis in A549 and NCI-H460 cells, which may be attributed to the activation of p53-mediated cascades. Therefore, bergapten may be beneficial for NSCLC treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Bergapten induces G1 arrest of non‑small cell lung cancer cells, associated with the p53‑mediated cascade

Chiang

Lin

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

show abstract

“…Because the majority of patients are diagnosed at later or metastatic stages, chemotherapy or palliative treatment is the main therapeutic schedule. 3 , 4 Combination chemotherapy is effective in the treatment of cancer for its benefits, which include maximized therapeutic efficacy, reduced side effects and overcome drug resistance. 5 Based on a large number of clinical trials, treatment with platinum-based combination chemotherapy is considered the first-line therapy for patients with advanced NSCLC and superior to the single-agent treatment in terms of overall survival.…”

Section: Introductionmentioning

confidence: 99%

Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer

Zhang¹,

Ru²,

Gao³

et al. 2017

DDDT

View full text Add to dashboard Cite

PurposeCisplatin plus gemcitabine (GEM) is a standard regimen for the first-line treatment of advanced non-small cell lung cancer. The aim of this study was to prepare biocompatible and biodegradable polymeric prodrugs and construct nanoparticles (NPs) with layer-by-layer (LbL) technique.MethodsPlatinum (Pt) (IV) complex with a carboxyl group was conjugated to the amino group of chitosan (CH), resulting in a CH-Pt conjugation with positive charge. GEM with amino group was conjugated to the carboxyl group of hyaluronic acid (HA), resulting in a HA-GEM conjugation with negative charge. Novel LbL NPs consisting of the CH-Pt core and the HA-GEM layer, named as HA-GEM/CH-Pt NPs, were constructed. The physicochemical properties of the HA-GEM/CH-Pt NPs were investigated. In vitro cytotoxicity against human non-small lung cancer cells (NCl-H460 cells) was investigated, and in vivo antitumor efficiency was evaluated on mice bearing NCl-H460 cells xenografts.ResultsHA-GEM/CH-Pt NPs have a size of about 187 nm, a zeta potential value of −21 mV and high drug encapsulation efficiency of 90%. The drug release of HA-GEM/CH-Pt NPs exhibited a sustained behavior. HA-GEM/CH-Pt NPs could significantly enhance in vitro cytotoxicity and in vivo antitumor effect against lung cancer animal model compared to the single-drug-loaded NPs and free drug solutions.ConclusionThe results demonstrated that the HA-GEM/CH-Pt NPs might be a promising system for the synergetic treatment of lung carcinoma.

show abstract

“…Figure 3 highlights some of the cancer gene therapies using different biological payloads. [55][56][57][58][59][60][61] Of which, RNA interference is one of the most versatile techniques employed to selectively block gene expression in the cell. [62] Chen et al have showed that the mouse double minute 2 homolog (MDM2) gene inhibiting small interfering RNA (siRNA) improves the efficiency of gene silencing to 83.55 % when coupled with amino-functionalized SWCNTs.…”

Section: Cancer Therapymentioning

confidence: 99%

“…Gene silencing using nanotubes as a carrier has achieved significant success in suppressing the growth of cancer cells. Figure highlights some of the cancer gene therapies using different biological payloads . Of which, RNA interference is one of the most versatile techniques employed to selectively block gene expression in the cell .…”

Section: Introductionmentioning

confidence: 99%

Derivatized Carbon Nanotubes for Gene Therapy in Mammalian and Plant Cells

et al. 2020

View full text Add to dashboard Cite

The concept of gene vectors for therapeutic applications has been known for several years, but it is far from revealing its actual potential. With the advent of hollow cylindrical carbon nanomaterials such as carbon nanotubes (CNTs), researchers have invented several new tools to deliver genes at the required site of action in mammalian and plant cells. The ease of diversified functionalization has allowed CNTs to be by far the most adaptable non‐viral vector for gene therapy. This Minireview addresses the dexterity with which CNTs undergo surface modifications and their applications as a potent vector in gene therapy of humans and plants. Specifically, we will discuss the new tools that scientific communities have invented to achieve gene therapy using plasmid DNA, RNA silencing, suicide gene therapy, and plant genetic engineering. Additionally, we will shed some light on the mechanism of gene transportation using carbon nanotubes in cancer cells and plants.

show abstract

Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer

Cited by 19 publications

References 38 publications

Bergapten induces G1 arrest of non‑small cell lung cancer cells, associated with the p53‑mediated cascade

Bergapten induces G1 arrest of non‑small cell lung cancer cells, associated with the p53‑mediated cascade

Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer

Derivatized Carbon Nanotubes for Gene Therapy in Mammalian and Plant Cells

Contact Info

Product

Resources

About